Document Classification

Section Type: RESULTS

Text: The most common serious adverse events were neutropenia (n = 5 [3 %] in the control group, n = 3 [1 %] in the single-dose oral casopitant mesylate group, and n = 11 [4 %] in the 3-day intravenous plus oral casopitant mesylate group), febrile neutropenia (n = 1 [< 1 %] in the control group, n = 4 [1 %] in the single-dose oral casopitant mesylate group, and n = 6 [2 %] in the 3-day intravenous plus oral casopitant mesylate group), and dehydration (n = 4 [2 %] in the control group, n = 2 [< 1 %] in the single-dose oral casopitant mesylate group, and n = 1 [< 1 %] in the 3-day intravenous plus oral casopitant mesylate group).